-
公开(公告)号：US20140057965A1
公开(公告)日：2014-02-27
申请号：US14069642
申请日：2013-11-01
IPC分类号： C12N15/113 , A61K31/713
CPC分类号： C12N15/1137 , A61K31/713 , C12N2310/14 , C12N2310/314 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/3233 , C12N2310/3515 , C12N2310/531 , Y02A50/385 , C12N2310/3521
摘要： The invention relates to double-stranded ribonucleic acids (dsRNAs) targeting gene expression of phosphatidylinositol 4-kinase (PI4K), in particular human phosphatidylinositol 4-kinase, catalytic, beta polypeptide (PIK4CB) or human phosphatidylinositol 4-kinase, catalytic, alpha polypeptide (PIK4CA), and their use for treating infection by positive stranded RNA viruses such as hepatitis C virus (HCV). Each dsRNA comprises an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the PIK4CB or PIK4CA target mRNA. A plurality of such dsRNA may be employed to provide therapeutic benefit. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier, and including a delivery modality such as fully encapsulated liposomes or lipid complexes. The invention further includes methods for treating diseases caused by positive stranded RNA virus infection using the pharmaceutical compositions; and methods for inhibiting the propogation of positive stranded RNA viruses in and between cells.
摘要翻译： 本发明涉及靶向磷脂酰肌醇4-激酶（PI4K）的基因表达的双链核糖核酸（dsRNA），特别是人磷脂酰肌醇4-激酶，催化的β多肽（PIK4CB）或人磷脂酰肌醇4-激酶，催化的α多肽 （PIK4CA），以及它们用于治疗由正链RNA病毒如丙型肝炎病毒（HCV）感染的用途。 每个dsRNA包含具有长度小于30个核苷酸的核苷酸序列的反义链，其长度通常为19-25个核苷酸，并且其与至少一部分PIK4CB或PIK4CA靶mRNA基本上互补。 可以使用多种这样的dsRNA来提供治疗益处。 本发明还涉及包含dsRNA与药学上可接受的载体的药物组合物，并且包括递送方式如完全包封的脂质体或脂质复合物。 本发明还包括使用药物组合物治疗由正链RNA病毒感染引起的疾病的方法; 以及用于抑制细胞内和细胞内的正链RNA病毒传播的方法。
-
公开(公告)号：US20100183704A1
公开(公告)日：2010-07-22
申请号：US12562349
申请日：2009-09-18
IPC分类号： A61K9/127 , C12N5/00 , C12N5/02 , C12N15/63 , A61P31/14 , A61K31/7088 , C07H21/02 , A61P31/20
CPC分类号： C12N15/1137 , C12N2310/14 , C12N2310/315 , C12N2310/321 , C12N2310/3515 , C12N2310/3521
摘要： The invention relates to double-stranded ribonucleic acids (dsRNAs) targeting gene expression carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase (CAD), and their use for treating infection by positive stranded RNA viruses such as hepatitis C virus (HCV). Each dsRNA comprises an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the CAD target mRNA. A plurality of such dsRNA may be employed to provide therapeutic benefit. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier, and including a delivery modality such as fully encapsulated liposomes or lipid complexes. The invention further includes methods for treating diseases caused by positive stranded RNA virus infection using the pharmaceutical compositions; and methods for inhibiting the propagation of positive stranded RNA viruses in and between cells.
摘要翻译： 本发明涉及靶向基因表达氨基甲酰磷酸合成酶2，天冬氨酸转氨甲酰酶和二氢激酶（CAD）的双链核糖核酸（dsRNA）及其用于治疗由正链RNA病毒如丙型肝炎病毒（HCV）感染的用途。 每个dsRNA包含具有长度小于30个核苷酸的核苷酸序列的反义链，其长度通常为19-25个核苷酸，并且其与至少一部分CAD靶mRNA基本互补。 可以使用多种这样的dsRNA来提供治疗益处。 本发明还涉及包含dsRNA与药学上可接受的载体的药物组合物，并且包括递送方式如完全包封的脂质体或脂质复合物。 本发明还包括使用药物组合物治疗由正链RNA病毒感染引起的疾病的方法; 以及用于抑制细胞内和细胞之间的正链RNA病毒繁殖的方法。
-
公开(公告)号：US08603995B2
公开(公告)日：2013-12-10
申请号：US13359129
申请日：2012-01-26
IPC分类号： C12N15/113 , C07H21/04
CPC分类号： C12N15/1137 , A61K31/713 , C12N2310/14 , C12N2310/314 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/3233 , C12N2310/3515 , C12N2310/531 , Y02A50/385 , C12N2310/3521
摘要： The invention relates to double-stranded ribonucleic acids (dsRNAs) targeting gene expression of phosphatidylinositol 4-kinase (PI4K), in particular human phosphatidylinositol 4-kinase, catalytic, beta polypeptide (PIK4CB) or human phosphatidylinositol 4-kinase, catalytic, alpha polypeptide (PIK4CA), and their use for treating infection by positive stranded RNA viruses such as hepatitis C virus (HCV). Each dsRNA comprises an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the PIK4CB or PIK4CA target mRNA. A plurality of such dsRNA may be employed to provide therapeutic benefit. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier, and including a delivery modality such as fully encapsulated liposomes or lipid complexes. The invention further includes methods for treating diseases caused by positive stranded RNA virus infection using the pharmaceutical compositions; and methods for inhibiting the propogation of positive stranded RNA viruses in and between cells.
-
公开(公告)号：US20120129913A1
公开(公告)日：2012-05-24
申请号：US13359129
申请日：2012-01-26
CPC分类号： C12N15/1137 , A61K31/713 , C12N2310/14 , C12N2310/314 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/3233 , C12N2310/3515 , C12N2310/531 , Y02A50/385 , C12N2310/3521
摘要： The invention relates to double-stranded ribonucleic acids (dsRNAs) targeting gene expression of phosphatidylinositol 4-kinase (PI4K), in particular human phosphatidylinositol 4-kinase, catalytic, beta polypeptide (PIK4CB) or human phosphatidylinositol 4-kinase, catalytic, alpha polypeptide (PIK4CA), and their use for treating infection by positive stranded RNA viruses such as hepatitis C virus (HCV). Each dsRNA comprises an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the PIK4CB or PIK4CA target mRNA. A plurality of such dsRNA may be employed to provide therapeutic benefit. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier, and including a delivery modality such as fully encapsulated liposomes or lipid complexes. The invention further includes methods for treating diseases caused by positive stranded RNA virus infection using the pharmaceutical compositions; and methods for inhibiting the propogation of positive stranded RNA viruses in and between cells.
摘要翻译： 本发明涉及靶向磷脂酰肌醇4-激酶（PI4K）的基因表达的双链核糖核酸（dsRNA），特别是人磷脂酰肌醇4-激酶，催化的β多肽（PIK4CB）或人磷脂酰肌醇4-激酶，催化的α多肽 （PIK4CA），以及它们用于治疗由正链RNA病毒如丙型肝炎病毒（HCV）感染的用途。 每个dsRNA包含具有长度小于30个核苷酸的核苷酸序列的反义链，其长度通常为19-25个核苷酸，并且其与至少一部分PIK4CB或PIK4CA靶mRNA基本上互补。 可以使用多种这样的dsRNA来提供治疗益处。 本发明还涉及包含dsRNA与药学上可接受的载体的药物组合物，并且包括递送方式如完全包封的脂质体或脂质复合物。 本发明还包括使用药物组合物治疗由正链RNA病毒感染引起的疾病的方法; 以及用于抑制细胞内和细胞内的正链RNA病毒传播的方法。
-
公开(公告)号：US09045546B2
公开(公告)日：2015-06-02
申请号：US13690269
申请日：2012-11-30
CPC分类号： C07K16/30 , C07K16/28 , C07K2317/34 , C07K2317/77
摘要： The present invention provides molecules that bind to TMEM16A (“TMEM16A binding molecules”), particularly human or humanized antibodies and antibody drug conjugates that bind to human TMEM16A and modulate its functions. Epitopes of TMEM16A and molecules that bind these epitopes are also provided herein.
摘要翻译： 本发明提供结合TMEM16A（“TMEM16A结合分子”）的分子，特别是结合人TMEM16A并调节其功能的人或人源化抗体和抗体药物偶联物。 TMEM16A的表位和结合这些表位的分子也在本文中提供。
-
公开(公告)号：US08748587B2
公开(公告)日：2014-06-10
申请号：US13485311
申请日：2012-05-31
IPC分类号： C07K16/30 , C07K16/46 , A61K39/395
CPC分类号： C07K16/28 , C07K2317/34 , C07K2317/77
摘要： The present invention provides molecules that bind to TMEM16A (“TMEM16A binding molecules”), particularly human or humanized antibodies and antibody drug conjugates that bind to human TMEM16A and modulate its functions. Epitopes of TMEM16A and molecules that bind these epitopes are also provided herein.
摘要翻译： 本发明提供结合TMEM16A（“TMEM16A结合分子”）的分子，特别是结合人TMEM16A并调节其功能的人或人源化抗体和抗体药物偶联物。 TMEM16A的表位和结合这些表位的分子也在本文中提供。
-
公开(公告)号：US20100183613A1
公开(公告)日：2010-07-22
申请号：US12582242
申请日：2009-10-20
IPC分类号： A61K39/395 , A61K31/713 , A61K38/02 , A61K31/357 , A61K31/7088 , A61P31/14
CPC分类号： C12N9/88 , C12N15/1137 , C12N2310/14 , C12Y401/01033
摘要： The present invention provides novel methods of reducing Flavivirus viral replication and/or infection, e.g., Dengue virus. The invention employs mevalonate decarboxylase (MVD) antagonists to inhibit the cholesterol biosynthesis pathway, thereby inhibiting viral replication/infection.
摘要翻译： 本发明提供了减少黄病毒病毒复制和/或感染的新方法，例如登革热病毒。 本发明使用甲羟戊酸脱羧酶（MVD）拮抗剂抑制胆固醇生物合成途径，从而抑制病毒复制/感染。
-
公开(公告)号：US20120308582A1
公开(公告)日：2012-12-06
申请号：US13485311
申请日：2012-05-31
IPC分类号： C07K16/30 , A61P35/00 , A61K39/395
CPC分类号： C07K16/28 , C07K2317/34 , C07K2317/77
摘要： The present invention provides molecules that bind to TMEM16A (“TMEM16A binding molecules”), particularly human or humanized antibodies and antibody drug conjugates that bind to human TMEM16A and modulate its functions. Epitopes of TMEM16A and molecules that bind these epitopes are also provided herein.
摘要翻译： 本发明提供了结合TMEM16A（TMEM16A结合分子），特别是结合人TMEM16A并调节其功能的人或人源化抗体和抗体药物偶联物的分子。 TMEM16A的表位和结合这些表位的分子也在本文中提供。
-
公开(公告)号：US20100316573A1
公开(公告)日：2010-12-16
申请号：US12446430
申请日：2007-10-17
申请人： Larry Alexander Gaither , Vadim Iourgenko , Mark Aron Labow , Dale Alan Porter , Christopher Sean Straub , Yao Yao , Leigh Zawel
发明人： Larry Alexander Gaither , Vadim Iourgenko , Mark Aron Labow , Dale Alan Porter , Christopher Sean Straub , Yao Yao , Leigh Zawel
IPC分类号： A61K49/00 , A61K31/4439 , C07D401/02 , A61P9/00 , A61P29/00 , A61P35/00 , A61P37/00
CPC分类号： G01N33/574 , G01N33/6869 , G01N2333/525
摘要： A method to predict which patients will respond to a IAP inhibiting compound comprising: a) administering an IAP inhibitor compound to a patient, and b) measuring TNF-α or IL-β levels.
摘要翻译： 一种预测哪些患者将对IAP抑制化合物作出反应的方法，包括：a）向患者施用IAP抑制剂化合物，和b）测量TNF-α或IL- 水平。
-
公开(公告)号：US20100184823A1
公开(公告)日：2010-07-22
申请号：US12667631
申请日：2008-07-04
IPC分类号： A61K31/7088 , C07H21/02 , C12N5/10 , A61K9/127 , C12N5/02
CPC分类号： C12N15/1137 , A61K31/713 , C12N2310/14 , C12N2310/314 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/3233 , C12N2310/3515 , C12N2310/531 , Y02A50/385 , C12N2310/3521
摘要： The invention relates to double-stranded ribonucleic acids (dsRNAs) targeting gene expression of phosphatidylinositol 4-kinase (PI4K), in particular human phosphatidylinositol 4-kinase, catalytic, beta polypeptide (PIK4CB) or human phosphatidylinositol 4-kinase, catalytic, alpha polypeptide (PIK4CA), and their use for treating infection by positive stranded RNA viruses such as hepatitis C virus (HCV). Each dsRNA comprises an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the PIK4CB or PIK4CA target mRNA. A plurality of such dsRNA may be employed to provide therapeutic benefit. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier, and including a delivery modality such as fully encapsulated liposomes or lipid complexes. The invention further includes methods for treating diseases caused by positive stranded RNA virus infection using the pharmaceutical compositions; and methods for inhibiting the propagation of positive stranded RNA viruses in and between cells.
摘要翻译： 本发明涉及靶向磷脂酰肌醇4-激酶（PI4K）的基因表达的双链核糖核酸（dsRNA），特别是人磷脂酰肌醇4-激酶，催化的β多肽（PIK4CB）或人磷脂酰肌醇4-激酶，催化的α多肽 （PIK4CA），以及它们用于治疗由正链RNA病毒如丙型肝炎病毒（HCV）感染的用途。 每个dsRNA包含具有长度小于30个核苷酸的核苷酸序列的反义链，其长度通常为19-25个核苷酸，并且其与至少一部分PIK4CB或PIK4CA靶mRNA基本上互补。 可以使用多种这样的dsRNA来提供治疗益处。 本发明还涉及包含dsRNA与药学上可接受的载体的药物组合物，并且包括递送方式如完全包封的脂质体或脂质复合物。 本发明还包括使用药物组合物治疗由正链RNA病毒感染引起的疾病的方法; 以及用于抑制细胞内和细胞之间的正链RNA病毒繁殖的方法。
-
-
-
-
-
-
-
-
-
搜索结果
10 条记录 (耗时 0.029 秒)
